Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 in Patients With Primary Hypercholesterolemia and Essential Hypertension

The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Condition or disease : Primary Hypercholesterolemia and Essential Hypertension Intervention/treatment Drug : AD-2021 Drug : AD-2022 Drug : AD-2021 Placebo Drug : AD-2022 Placebo Phase : Phase 3

Inclusion Criteria:

• Signed informed consent
• Subjects with hypertension and hyperlipidemia

Exclusion Criteria:

• Patient with known or suspected secondary hypertension
• Other exclusions applied